Difference between revisions of "Part:BBa K1633004"

 
 
Line 1: Line 1:
−
 
 
__NOTOC__
 
__NOTOC__
 
<partinfo>BBa_K1633004 short</partinfo>
 
<partinfo>BBa_K1633004 short</partinfo>
Line 13: Line 12:
 
<partinfo>BBa_K1633004 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K1633004 SequenceAndFeatures</partinfo>
  
 +
 +
<!-- Uncomment this to enable Functional Parameter display
 +
===Functional Parameters===
 +
<partinfo>BBa_K1633004 parameters</partinfo>
 +
<!-- -->
 +
 +
 +
==== USAGE AND BIOLOGY ====
 +
 +
We package MOR siRNA into exosomes by transfecting HEK293 cells with a a Lamp2b-RVG plasmid and the MOR siRNA-2 plasmid and then collect siRNA-encapsulated exosomes. When inject the modified exosomes into the bloodstream, exosome will specifically recognize acetylcholine receptors and fuse with neurons under the direction of the RVG peptide. Once inside neurons, MOR siRNA will degrade MOR mRNA by base-pairing, resulting in sharp decrease of MOR on neuron membrane. As a consequence, MOR reduction and disturbed function will result in the inhabitation of the secretion of GABA and the suppression of the dopaminergic reward pathway, which ultimately have some therapeutic effects on opioid dependence.
 +
 +
==== CHARACTERIZATION ====
 +
 +
====== Interference efficiency of MOR siRNA-2 plasmid ======
 +
 +
To ensure the interference efficiency,MOR siRNA-2 plasmid was transfected into the mouse neuroblastoma cell line Neuro2A. Efficient knockdown of MOR by MOR siRNA-2 in Neuro2A cells is observed.
 +
 +
[[File:NJU-China-parts-fig 4.png|300px]]
 +
 +
Figure 2. Relative level of MOR mRNA in Neuro2A cell after transfection of MOR siRNA-2 plasmid.
 +
 +
====== Package of MOR siRNA into exosomes ======
 +
 +
The levels of MOR siRNA in isolated exosomes were assayed by a quantitative RT-PCR assay. The MOR siRNA concentration in exosomes was calculated to be approximately 80 fmol/μg. The results showed that MOR siRNA can be successfully packaged into exosomes, no matter the exosomes were modified on the outside membrane with or without RVG peptide.
 +
 +
[[File:NJU-China-parts-fig 5.png|250px]]
 +
 +
Figure 3. The concentration of MOR siRNA in unmodified or RVG-modified exosomes.
 +
 +
====== TEM photographs of exosomes carrying MOR siRNA inside and RVG on membranes ======
 +
 +
We next characterized the RVG exosomes loaded with MOR siRNA using transmission electron microscopy (TEM). The TEM photographs showed that the exosomes presented normal morphological characteristics after outside modification and siRNA loading, with a diameter of approximately 90 nm and a double-layer membrane surrounded. These characteristics indicate that the exosome properties were not affected by the modifications.
 +
 +
[[File:NJU-China-parts-fig6.jpg|250px]]
 +
 +
Figure 4. TEM photographs of the exosomes with outside RVG modification and inside siRNA loading.
 +
 +
====== RVG exosomes specifically deliver MOR siRNA into neuronal cells  ======
 +
 +
Subsequently, MOR siRNA levels were assayed in recipient Neuro2A cells when incubating with RVG exosomes loaded with MOR siRNA. The siRNAs concentrations were barely detected in untreated control cells or in cells treated with RVG exosomes or unmodified exosomes loaded with MOR siRNA. In contrast, a significant amount of siRNAs were detected in Neuro2A cells after treatment with RVG exosomes loaded with MOR siRNA. As a control, MOR siRNA was also barely detected in C2C12 cells treated with RVG-exosome loaded with MOR siRNA. Taken together, these results clearly demonstrate that the RVG peptide modification on the exosome membrane specifically guides exosomes to target neuronal cells bearing the surface acetylcholine receptor, allowing for the efficient delivery of MOR siRNA into the recipient cells.
 +
 +
[[File:NJU-China-parts-fig 7.png|300px]]
 +
 +
Figure 5. Quantitative RT-PCR analysis of MOR siRNA concentration in Neuro2A and C2C12 cells treated with RVG exosomes (RVG exosome), unmodified exosomes loaded with MOR siRNA (siRNA-exosome) or RVG exosomes loaded with MOR siRNA (siRNA-RVG exosome).
 +
 +
====== RVG exosomes loaded with MOR siRNA specifically reduce MOR expression in neuronal cells  ======
 +
 +
We next evaluate the effect of RVG exosome-delivered siRNA on MOR expression in vitro. MOR expression levels were assayed in Neuro2A cells after treatment with RVG exosomes loaded with MOR siRNA. Compared with control cells, MOR protein and mRNA levels were dramatically reduced by RVG exosome-delivered siRNA, while no reduction in the MOR protein and mRNA levels were observed by exosomes without the RVG peptide on their surface. The results suggest that the RVG peptide modification on the exosome membrane can specifically guides exosomes to target neuronal cells, allowing for the delivery of MOR siRNA into the neuronal cells to reduce MOR expression levels.
 +
 +
[[File:NJU-China-parts-fig8.jpg|300px]] [[File:NJU-China-parts-fig8B.png|200px]]
 +
 +
Figure 6. RVG exosome-delivered siRNA specifically enters Neuro2A cells and reduce MOR expression. Left panel: Western blot analysis of MOR protein levels in untreated control Neuro2A cells or cells treated with MOR siRNA loaded in normal exosomes or RVG exosomes. Right panel: qRT-PCR analysis of MOR mRNA levels in untreated control Neuro2A cells or cells treated with MOR siRNA loaded in normal exosomes or RVG exosomes.
 +
 +
====== The effects of siRNA delivered by RVG exosomes on morphine-induced CPP  ======
 +
 +
MOR and its signaling pathway are known to be involved in the dependence and relapse of opioids such as morphine and heroin. Importantly, relapse always disrupts the process of opioid withdrawal. Subsequently, we focus on investigating the effect of exosomal siRNA of MOR on opioid relapse. We evaluate the consequences of MOR knockdown by exosomal siRNA in the animals by conducting the morphine-induced conditioned place preference (CPP) test, a mouse model for morphine wanting/liking behaviors. In the CPP paradigm, mice learned to associate the rewarding effect of morphine with a drug-paired environment. The CPP test was designed to mimick the process of relapse of morphine. Before conditioning, the mice showed a preference for visiting black chamber. Then, morphine dependence was developed when mice were place-conditioned by intraperitoneal injection with morphine in the white chamber on even-numbered days (on days 2, 4, 6, 8 and 10) and with saline in the black chamber on odd-numbered days (on days 3, 5, 7, 9 and 11). On day 12, CPP test 1 was conducted by allowing the mice to freely visit the morphine-paired white chamber or saline-paired black chambers. As expected, mice showed a significant preference in visiting the morphine-paired white chamber, suggesting the development of morphine dependence. Then, morphine treatment was removed for several days. On day 26, CPP test 2 was conducted and mice spent less time in the morphine-paired white chamber than the saline-paired black chamber, suggesting the disappearance of morphine dependence. Then, mice were intravenously injected with saline or with siRNAs loaded in normal exosome or RVG exosome once every two days for a total of four times, and CPP test 3 was performed on day 32. Mice maintained their natural preference for the black chamber, suggesting that MOR siRNA had no effect on the behavior of the mice. Finally, mice were relapsed on morphine on day 33, and CPP test 4 was performed the next day. Interestingly, the mice treated with RVG exosome-delivered siRNAs maintained their natural preference for the black chamber, while the mice treated with saline or with siRNAs loaded in normal exosome show preference to morphine-paired white chamber, suggesting that the MOR siRNAs delivered by RVG exosome restrain drug addiction when the mice were re-exposed to morphine.
 +
 +
[[File:NJU-China-parts-fig9.png|500px]]
 +
 +
[[File:NJU-China-parts-CPP.jpg|700px]]
 +
 +
Figure 7. The effects of siRNA delivered by RVG exosomes on morphine-induced CPP. The upper panel is represented by the value of the time mice stay in morphine-paired white chamber minus the time mice stay in saline-paired black chamber. The lower panel is the representives of the heatmap of the mouse mobility.
 +
 +
====== The effects of siRNA delivered by RVG exosomes on MOR expression in vivo  ======
 +
 +
After the CPP test, mice were sacrificed, and total RNA and protein were extracted from mouse brain to evaluate the expression levels of MOR in vivo. Both MOR protein and mRNA levels were reduced in the mice treated with RVG exosome-delivered siRNA. In contrast, siRNAs delivered by unmodified exosome could not reduce MOR mRNA and protein levels in mouse brain. Thus, these results clearly demonstrate that exosomes with RVG modification passed through the BBB and delivered MOR siRNA into the central nervous system to regulate MOR expression, while natural exosomes without the RVG modification were not capable of delivering siRNA into the central nervous system or regulating target gene expression.
 +
 +
[[File:NJU-China-parts-fig10.jpg|300px]]  [[File:NJU-China-parts-fig10B.png|250px]]
 +
 +
Figure 8. RVG exosomes can transfer MOR siRNA through the BBB and reduce MOR expression levels in vivo. Left panel: Western blot analysis of MOR protein levels in the brains of mice following injection with saline or with MOR siRNA loaded in normal exosomes or RVG exosomes. Right panel: qRT-PCR analysis of MOR mRNA levels in the brains of mice following injection with saline or with MOR siRNA loaded in normal exosomes or RVG exosomes.
  
 
<!-- Uncomment this to enable Functional Parameter display  
 
<!-- Uncomment this to enable Functional Parameter display  

Latest revision as of 19:26, 18 September 2015

MOR siRNA-2 (siRNA for mouse Mu opioid receptor)

This part is a short hairpin RNA (shRNA) sequence. When this shRNA sequence is cut by restriction enzyme and then integrated into pcDNA 6.2 vector, this shRNA can play a RNAi function in mammalian cell lines such as HEK293 cell. When the shRNA vector of MOR is transfected into HEK293 cells, the shRNA hairpin structure is cleaved by Dicer into siRNA of MOR and loaded into the RISC. The siRNA-RISC complex targets at Mus musculus MOR mRNA under the guide of siRNA sequence and cleave the MOR mRNA.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]



USAGE AND BIOLOGY

We package MOR siRNA into exosomes by transfecting HEK293 cells with a a Lamp2b-RVG plasmid and the MOR siRNA-2 plasmid and then collect siRNA-encapsulated exosomes. When inject the modified exosomes into the bloodstream, exosome will specifically recognize acetylcholine receptors and fuse with neurons under the direction of the RVG peptide. Once inside neurons, MOR siRNA will degrade MOR mRNA by base-pairing, resulting in sharp decrease of MOR on neuron membrane. As a consequence, MOR reduction and disturbed function will result in the inhabitation of the secretion of GABA and the suppression of the dopaminergic reward pathway, which ultimately have some therapeutic effects on opioid dependence.

CHARACTERIZATION

Interference efficiency of MOR siRNA-2 plasmid

To ensure the interference efficiency,MOR siRNA-2 plasmid was transfected into the mouse neuroblastoma cell line Neuro2A. Efficient knockdown of MOR by MOR siRNA-2 in Neuro2A cells is observed.

NJU-China-parts-fig 4.png

Figure 2. Relative level of MOR mRNA in Neuro2A cell after transfection of MOR siRNA-2 plasmid.

Package of MOR siRNA into exosomes

The levels of MOR siRNA in isolated exosomes were assayed by a quantitative RT-PCR assay. The MOR siRNA concentration in exosomes was calculated to be approximately 80 fmol/μg. The results showed that MOR siRNA can be successfully packaged into exosomes, no matter the exosomes were modified on the outside membrane with or without RVG peptide.

NJU-China-parts-fig 5.png

Figure 3. The concentration of MOR siRNA in unmodified or RVG-modified exosomes.

TEM photographs of exosomes carrying MOR siRNA inside and RVG on membranes

We next characterized the RVG exosomes loaded with MOR siRNA using transmission electron microscopy (TEM). The TEM photographs showed that the exosomes presented normal morphological characteristics after outside modification and siRNA loading, with a diameter of approximately 90 nm and a double-layer membrane surrounded. These characteristics indicate that the exosome properties were not affected by the modifications.

NJU-China-parts-fig6.jpg

Figure 4. TEM photographs of the exosomes with outside RVG modification and inside siRNA loading.

RVG exosomes specifically deliver MOR siRNA into neuronal cells

Subsequently, MOR siRNA levels were assayed in recipient Neuro2A cells when incubating with RVG exosomes loaded with MOR siRNA. The siRNAs concentrations were barely detected in untreated control cells or in cells treated with RVG exosomes or unmodified exosomes loaded with MOR siRNA. In contrast, a significant amount of siRNAs were detected in Neuro2A cells after treatment with RVG exosomes loaded with MOR siRNA. As a control, MOR siRNA was also barely detected in C2C12 cells treated with RVG-exosome loaded with MOR siRNA. Taken together, these results clearly demonstrate that the RVG peptide modification on the exosome membrane specifically guides exosomes to target neuronal cells bearing the surface acetylcholine receptor, allowing for the efficient delivery of MOR siRNA into the recipient cells.

NJU-China-parts-fig 7.png

Figure 5. Quantitative RT-PCR analysis of MOR siRNA concentration in Neuro2A and C2C12 cells treated with RVG exosomes (RVG exosome), unmodified exosomes loaded with MOR siRNA (siRNA-exosome) or RVG exosomes loaded with MOR siRNA (siRNA-RVG exosome).

RVG exosomes loaded with MOR siRNA specifically reduce MOR expression in neuronal cells

We next evaluate the effect of RVG exosome-delivered siRNA on MOR expression in vitro. MOR expression levels were assayed in Neuro2A cells after treatment with RVG exosomes loaded with MOR siRNA. Compared with control cells, MOR protein and mRNA levels were dramatically reduced by RVG exosome-delivered siRNA, while no reduction in the MOR protein and mRNA levels were observed by exosomes without the RVG peptide on their surface. The results suggest that the RVG peptide modification on the exosome membrane can specifically guides exosomes to target neuronal cells, allowing for the delivery of MOR siRNA into the neuronal cells to reduce MOR expression levels.

NJU-China-parts-fig8.jpg NJU-China-parts-fig8B.png

Figure 6. RVG exosome-delivered siRNA specifically enters Neuro2A cells and reduce MOR expression. Left panel: Western blot analysis of MOR protein levels in untreated control Neuro2A cells or cells treated with MOR siRNA loaded in normal exosomes or RVG exosomes. Right panel: qRT-PCR analysis of MOR mRNA levels in untreated control Neuro2A cells or cells treated with MOR siRNA loaded in normal exosomes or RVG exosomes.

The effects of siRNA delivered by RVG exosomes on morphine-induced CPP

MOR and its signaling pathway are known to be involved in the dependence and relapse of opioids such as morphine and heroin. Importantly, relapse always disrupts the process of opioid withdrawal. Subsequently, we focus on investigating the effect of exosomal siRNA of MOR on opioid relapse. We evaluate the consequences of MOR knockdown by exosomal siRNA in the animals by conducting the morphine-induced conditioned place preference (CPP) test, a mouse model for morphine wanting/liking behaviors. In the CPP paradigm, mice learned to associate the rewarding effect of morphine with a drug-paired environment. The CPP test was designed to mimick the process of relapse of morphine. Before conditioning, the mice showed a preference for visiting black chamber. Then, morphine dependence was developed when mice were place-conditioned by intraperitoneal injection with morphine in the white chamber on even-numbered days (on days 2, 4, 6, 8 and 10) and with saline in the black chamber on odd-numbered days (on days 3, 5, 7, 9 and 11). On day 12, CPP test 1 was conducted by allowing the mice to freely visit the morphine-paired white chamber or saline-paired black chambers. As expected, mice showed a significant preference in visiting the morphine-paired white chamber, suggesting the development of morphine dependence. Then, morphine treatment was removed for several days. On day 26, CPP test 2 was conducted and mice spent less time in the morphine-paired white chamber than the saline-paired black chamber, suggesting the disappearance of morphine dependence. Then, mice were intravenously injected with saline or with siRNAs loaded in normal exosome or RVG exosome once every two days for a total of four times, and CPP test 3 was performed on day 32. Mice maintained their natural preference for the black chamber, suggesting that MOR siRNA had no effect on the behavior of the mice. Finally, mice were relapsed on morphine on day 33, and CPP test 4 was performed the next day. Interestingly, the mice treated with RVG exosome-delivered siRNAs maintained their natural preference for the black chamber, while the mice treated with saline or with siRNAs loaded in normal exosome show preference to morphine-paired white chamber, suggesting that the MOR siRNAs delivered by RVG exosome restrain drug addiction when the mice were re-exposed to morphine.

NJU-China-parts-fig9.png

NJU-China-parts-CPP.jpg

Figure 7. The effects of siRNA delivered by RVG exosomes on morphine-induced CPP. The upper panel is represented by the value of the time mice stay in morphine-paired white chamber minus the time mice stay in saline-paired black chamber. The lower panel is the representives of the heatmap of the mouse mobility.

The effects of siRNA delivered by RVG exosomes on MOR expression in vivo

After the CPP test, mice were sacrificed, and total RNA and protein were extracted from mouse brain to evaluate the expression levels of MOR in vivo. Both MOR protein and mRNA levels were reduced in the mice treated with RVG exosome-delivered siRNA. In contrast, siRNAs delivered by unmodified exosome could not reduce MOR mRNA and protein levels in mouse brain. Thus, these results clearly demonstrate that exosomes with RVG modification passed through the BBB and delivered MOR siRNA into the central nervous system to regulate MOR expression, while natural exosomes without the RVG modification were not capable of delivering siRNA into the central nervous system or regulating target gene expression.

NJU-China-parts-fig10.jpg NJU-China-parts-fig10B.png

Figure 8. RVG exosomes can transfer MOR siRNA through the BBB and reduce MOR expression levels in vivo. Left panel: Western blot analysis of MOR protein levels in the brains of mice following injection with saline or with MOR siRNA loaded in normal exosomes or RVG exosomes. Right panel: qRT-PCR analysis of MOR mRNA levels in the brains of mice following injection with saline or with MOR siRNA loaded in normal exosomes or RVG exosomes.